Thermo Fisher Scientific Inc. (TMO) Shares Bought by Private Advisor Group LLC
Private Advisor Group LLC raised its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 5.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,573 shares of the medical research company’s stock after buying an additional 789 shares during the quarter. Private Advisor Group LLC’s holdings in Thermo Fisher Scientific were worth $2,813,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in TMO. Morgan Stanley boosted its holdings in shares of Thermo Fisher Scientific by 7.6% in the 1st quarter. Morgan Stanley now owns 4,664,882 shares of the medical research company’s stock worth $716,526,000 after purchasing an additional 327,826 shares during the period. Renaissance Technologies LLC boosted its holdings in shares of Thermo Fisher Scientific by 68.8% in the 1st quarter. Renaissance Technologies LLC now owns 1,373,044 shares of the medical research company’s stock worth $210,900,000 after purchasing an additional 559,400 shares during the period. BlackRock Inc. boosted its holdings in shares of Thermo Fisher Scientific by 2,692.1% in the 1st quarter. BlackRock Inc. now owns 22,988,885 shares of the medical research company’s stock worth $3,531,095,000 after purchasing an additional 22,165,530 shares during the period. KCG Holdings Inc. boosted its holdings in shares of Thermo Fisher Scientific by 42.1% in the 1st quarter. KCG Holdings Inc. now owns 25,700 shares of the medical research company’s stock worth $3,948,000 after purchasing an additional 7,611 shares during the period. Finally, Investment Centers of America Inc. purchased a new position in shares of Thermo Fisher Scientific in the 1st quarter worth approximately $200,000. Institutional investors and hedge funds own 86.16% of the company’s stock.
In related news, CEO Marc N. Casper sold 50,000 shares of the company’s stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $188.39, for a total transaction of $9,419,500.00. Following the transaction, the chief executive officer now directly owns 252,577 shares of the company’s stock, valued at approximately $47,582,981.03. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 0.49% of the company’s stock.
A number of equities analysts have recently commented on TMO shares. Cowen reiterated a “buy” rating and issued a $200.00 target price on shares of Thermo Fisher Scientific in a report on Friday, September 1st. Argus reiterated a “buy” rating on shares of Thermo Fisher Scientific in a report on Tuesday, August 22nd. They noted that the move was a valuation call. Zacks Investment Research upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $208.00 target price for the company in a report on Thursday, September 7th. Goldman Sachs Group began coverage on Thermo Fisher Scientific in a report on Tuesday, September 26th. They set a “buy” rating and a $225.00 price objective for the company. Finally, Deutsche Bank set a $226.00 price objective on Thermo Fisher Scientific and gave the company a “buy” rating in a report on Thursday, October 26th. One investment analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $205.21.
Thermo Fisher Scientific Inc. (NYSE TMO) opened at $192.27 on Monday. The company has a market capitalization of $77,099.31, a price-to-earnings ratio of 21.13, a PEG ratio of 1.76 and a beta of 1.06. The company has a debt-to-equity ratio of 0.85, a current ratio of 1.26 and a quick ratio of 0.81. Thermo Fisher Scientific Inc. has a 1 year low of $139.88 and a 1 year high of $201.20.
Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, October 25th. The medical research company reported $2.31 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.24 by $0.07. The firm had revenue of $5.12 billion during the quarter, compared to analyst estimates of $5.03 billion. Thermo Fisher Scientific had a return on equity of 15.94% and a net margin of 11.73%. The business’s revenue for the quarter was up 13.9% compared to the same quarter last year. During the same period in the previous year, the company posted $2.03 EPS. research analysts anticipate that Thermo Fisher Scientific Inc. will post 9.36 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Monday, January 15th. Stockholders of record on Friday, December 15th will be given a $0.15 dividend. This represents a $0.60 annualized dividend and a dividend yield of 0.31%. The ex-dividend date of this dividend is Thursday, December 14th. Thermo Fisher Scientific’s payout ratio is 10.19%.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with Analyst Ratings Network's FREE daily email newsletter.